Krebsmutationen: PIK3CA

A bit delayed again (see question of the week °27): We continue with the #cancer mutations and this time we are targeting mutations in #PIK3CA! But now more frequent again! So far we haven't been really happy with PIK3CA mutations: The clinical benefits of targeted therapy against these mutations are offset by pronounced #side effects - PIK3CA is important as a "switch" of insulin or similar growth factors for regulating the sugar balance, it leaves it completely "unpunished". don't inhibit yourself. This is so important because the mutations occur in a large number of types of cancer (without claiming to be exhaustive: breast cancer, lung cancer, glioma, bladder cancer, colon cancer, skin cancer, etc.). In addition to the targeted PIK3CA inhibition, there are also approaches to hit the entire signaling pathway by also evaluating mTOR or AKT as targets. What is most effective where and how and how classic chemotherapy, immunotherapy (ICB) or - in the case of breast cancer and prostate carcinoma - hormone-modulating therapies work in combination is the subject of clinical studies. PIK3CA vs PI3K: The entire protein is called PI3K. The kinase subunit is located on the PIK3CA gene. But both are often used interchangeably. 00:00 Cancer mutations: PIK3CA 00:09 What is that actually? [SKIP INTRO] 04:08 Which types of cancer are affected? 05:03 Where does that come from? 07:27 How do you treat that? 10:27 What's the research doing? 11:40 TAKE HOME Our video on nucleotide mutations:    • Krebsmutationen: Nukleotidmutationen   Our video about the amplification:    • Krebsmutationen: Amplifikationen   Our video about the mergers:    • Krebsmutationen: Fusionen, Translokationen   ___________________________ Created with: Microsoft PowerPoint Edited with: Final Cut Pro Music: "368" by Jobii [Epidemic Sound] Artwork: HealthCareSocialMedia